A Phase 2a Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-4482 in Healthy Participants Inoculated With Experimental Respiratory Syncytial Virus

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 22 May 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Molnupiravir (Primary)
Indications Chikungunya virus infections; COVID 2019 infections; Eastern equine encephalomyelitis; Ebola virus infections; Influenza virus infections; Middle East respiratory syndrome coronavirus; Renal failure; Respiratory syncytial virus infections; Severe acute respiratory syndrome; Venezuelan equine encephalomyelitis
Focus Therapeutic Use
Acronyms MK-4482-017
Sponsors Merck Sharp & Dohme Corp.

17 May 2023 Status changed from active, no longer recruiting to completed.
11 Apr 2023 Status changed from recruiting to active, no longer recruiting.
06 Mar 2023 Planned primary completion date changed from 22 Apr 2023 to 20 Apr 2023.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com